MedPath

Sanofi

Sanofi logo
🇫🇷France
Ownership
Public
Employees
87.9K
Market Cap
$141.3B
Website
http://www.sanofi.com
Introduction

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents

Phase 3
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-12-30
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Target Recruit Count
200
Registration Number
NCT00271258
Locations
🇫🇷

Sanofi-Aventis, Paris, France

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Phase 2
Terminated
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Drug: docetaxel and cisplatin
Radiation: radiotherapy
First Posted Date
2005-12-30
Last Posted Date
2009-12-23
Lead Sponsor
Sanofi
Target Recruit Count
14
Registration Number
NCT00271323
Locations
🇫🇷

Sanofi-Aventis, Paris, France

Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 1
Interventions
Drug: insulin glulisine / insulin glargine
Drug: insulin glulisin / insulin detemir
First Posted Date
2005-12-30
Last Posted Date
2009-12-07
Lead Sponsor
Sanofi
Target Recruit Count
88
Registration Number
NCT00271284
Locations
🇫🇷

Sanofi-Aventis Administrative Office, Paris, France

Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients

Phase 2
Completed
Conditions
Non Small Cell Lung Cancer
First Posted Date
2005-12-30
Last Posted Date
2009-12-07
Lead Sponsor
Sanofi
Target Recruit Count
40
Registration Number
NCT00271271
Locations
🇫🇷

Sanofi-Aventis, Paris, France

Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent Asthma

Phase 3
Completed
Conditions
Asthma
First Posted Date
2005-12-26
Last Posted Date
2005-12-28
Lead Sponsor
Sanofi
Target Recruit Count
450
Registration Number
NCT00270348

FOCUS:Focus On Coronary Unstable Syndromes

Phase 3
Completed
Conditions
Myocardial Ischemia
First Posted Date
2005-12-22
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Registration Number
NCT00268619

IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)

Phase 3
Completed
Conditions
Osteoporosis
First Posted Date
2005-12-22
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Registration Number
NCT00268632

Insulin Glargine in Type 2 Diabetes

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
First Posted Date
2005-12-22
Last Posted Date
2011-01-11
Lead Sponsor
Sanofi
Target Recruit Count
534
Registration Number
NCT00268645
Locations
🇹🇷

Sanofi-Aventis, Istanbul, Turkey

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Phase 2
Completed
Conditions
Prostatic Neoplasms
First Posted Date
2005-12-22
Last Posted Date
2009-12-07
Lead Sponsor
Sanofi
Registration Number
NCT00268710

Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)

Phase 1
Completed
Conditions
Head and Neck Neoplasms
First Posted Date
2005-12-22
Last Posted Date
2009-12-07
Lead Sponsor
Sanofi
Target Recruit Count
45
Registration Number
NCT00268671
© Copyright 2025. All Rights Reserved by MedPath